Hematology Oncology Fellowship
The Hematology Oncology Fellowship at Montefiore Medical Center and Albert Einstein College of Medicine provides comprehensive training in clinical practice, clinical investigation, and laboratory science. Established in 1959, our three and four-year programs offer an exceptional range of experience and research opportunities to fully prepare physicians for academic and clinical practice in hematology/oncology.
Our ACGME accredited fellowship program sponsors eight new fellows each year and includes rotations at Montefiore Medical Center, Jacobi Medical Center, and Lincoln Medical and Mental Health Center. Under the guidance of a staff of 28 hematology and oncology faculty members, including clinicians, scientists, and research scientists, fellows receive a thorough education in benign and malignant hematology, oncology, immunology and bone marrow transplantation. Fellows are responsible for consultations and ongoing care of inpatients and outpatients.
Because we serve a population of more than 1.6 million residents in the New York Metropolitan area, fellows are exposed to diverse cultures and a broad spectrum of hematologic and oncologic disorders. Our fellows consider multi-tiered diagnoses, ranging from various rare carcinomas to sickle cell disease. Fellows perform various types of bone marrow transplants, perform oncological gynecologic consults, hematological obstetric evaluations and see hematologic and oncologic transplant related complications.
The fellowship experience is constructed with a stronger emphasis on clinical hematology and oncology research than that of many other institutions. Working closely with one of our clinical investigators, fellows receive formal instruction on creating, executing, and interpreting clinical trials pertaining to thrombosis, hemoglobinopathy, stem cells, and phase 1 studies of breast and lung malignancies. Numerous unique educational and research opportunities are available to fellows, such as participating in twice a month research conferences and disease specific tumor boards. Tumor Boards consist of specialists from Surgery, Medical Oncology, Radiation Oncology, Radiology and Pathology form the centerpiece of the oncology-teaching program, as they evaluate and discuss patients for whom a multidisciplinary approach is being considered. A formal curriculum dealing with ethical, medicolegal, and socioeconomic issues is also integrated into the program.
Fellows fulfill 18 months of clinical rotations, with ample options to customize their individual training path in the second and third years under the guidance of a mentor. They can participate in basic science, molecular translational studies and clinical hematology and oncology research. Areas of interest in our institution include: colon cancer (basic molecular oncology, new prevention strategies and therapies), breast and lung cancer, phase 1 studies, promyelocytic leukemia, thrombosis, hemoglobinopathy, stem cell biology, TTP, von Willebrand's disease, red cell membrane defects, and cellular cation transportation. Fellows may elect to take 18 months in clinical electives instead of research.
Our Thrombosis and Sickle Cell programs and Cancer Center have greatly enhanced fellows' research experience for the past 30 years, resulting in new developments in diagnostic techniques, medications, procedures, and healthcare discoveries. The Thrombosis Program houses one of the largest thrombosis prevention treatment programs in the nation.
The fellowship program includes various regularly scheduled clinical case and research conferences, with excellent supervision by the faculty. We also offer the opportunity to pursue a Masters in Clinical Research. Benefits include four weeks vacation and stipend for conferences in 2nd and 3rd year. Fellows ascertain exceptional critical thinking and decision-making skills, proficiency with medical procedures, excellent patient care and teaching skills and unparalleled research skills. This is reflected in the fact that our fellows have been successful in passing both the hematology and oncology boards over the past several years.